title: Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections.
abstract: BACKGROUND
  Telavancin is approved in the USA and Canada for the treatment of Gram-positive complicated skin and skin structure infections (cSSSIs) based on the results of the Phase 3 Assessment of TeLAvancin in complicated Skin and skin structure infections (ATLAS) trials, which demonstrated non-inferiority of telavancin to vancomycin.
  
  
  METHODS
  We conducted a post hoc analysis of the ATLAS studies (ClinicalTrials.gov identifiers NCT00091819 and NCT00107978) to explore the efficacy of telavancin in patients with various types of cSSSIs.
  
  
  RESULTS
  A total of 1794 patients were included in this analysis; 1434 patients were clinically evaluable (CE) and 563 of these had methicillin-resistant Staphylococcus aureus (MRSA). Among CE patients with major abscesses (n = 619), cure rates were 91% for telavancin and 90% for vancomycin (95% CI for the difference -3.6 to 5.7). In patients with infective cellulitis (n = 519), cure was achieved in 87% and 88% of telavancin- and vancomycin-treated patients, respectively (95% CI for the difference -6.2 to 5.2). Cure rates in patients with wound infections were 85% in the telavancin group and 86% in the vancomycin group (95% CI for the difference -10.5 to 9.0). Cure rates for each type of cSSSI in patients infected with MRSA were also similar between the two treatment arms. Among CE patients infected with Panton-Valentine leucocidin (PVL)-positive MRSA (n = 447), cure rates were 93% for telavancin and 90% for vancomycin (95% CI for the difference -2.2 to 8.2).
  
  
  CONCLUSIONS
  Cure rates were similar for telavancin and vancomycin in patients with different types of cSSSIs, including infections caused by MRSA and PVL-positive strains of MRSA.
authors.affiliation: Department of Medicine and Division of Infectious Diseases, Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina. stryj001@mc.duke.edu
authors.forename: Martin E
authors.initials: ME
authors.lastname: Stryjewski
authors.forename: Steven L
authors.initials: SL
authors.lastname: Barriere
authors.forename: William
authors.initials: W
authors.lastname: O'Riordan
authors.forename: Lala M
authors.initials: LM
authors.lastname: Dunbar
authors.forename: Alan
authors.initials: A
authors.lastname: Hopkins
authors.forename: Fredric C
authors.initials: FC
authors.lastname: Genter
authors.forename: G Ralph
authors.initials: GR
authors.lastname: Corey
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000617:Aminoglycosides / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001427:Bacterial Toxins / Q000235:genetics; D005098:Exotoxins / Q000235:genetics; D005260:Female; D006801:Humans; D007956:Leukocidins / Q000235:genetics; D000077427:Lipoglycopeptides; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D013207:Staphylococcal Skin Infections / Q000188:drug therapy*; D016896:Treatment Outcome; D014481:United States; D037521:Virulence Factors / Q000235:genetics; D055815:Young Adult
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D001427:Bacterial Toxins; D005098:Exotoxins; D007956:Leukocidins; D000077427:Lipoglycopeptides; C078284:Panton-Valentine leukocidin; D037521:Virulence Factors; C487637:telavancin